Back to Journals » Cancer Management and Research » Volume 13

miR-302e Suppresses Glioma Progression by Targeting VEGFA [Retraction]

Authors Xie Y, Liu X, Hu T, Wang W

Received 16 March 2021

Accepted for publication 16 March 2021

Published 19 March 2021 Volume 2021:13 Pages 2653—2654

DOI https://doi.org/10.2147/CMAR.S311369


Xie Y, Liu X, Hu T, Wang W. Cancer Manage Res. 2020;12:10965–10974

The Editor-in-chief and Publisher of Cancer Management and Research wish to retract the published article. It was bought to the journal’s attention that some images in the article appeared to be duplicated with those from another article, Xu et al: Transcriptional regulation of miR-483-3p mediated by IL-6/STAT3 axis promoted epithelialmesenchymal transition and tumor stemness in glioma
(https://doi.org/10.18632/aging.103761).

● Figure 1D in the published article appears to be identical to Figure 1D in Xu et al but the data represents different experimental conditions and samples.
● Figure 7E in the published article appears to be identical to Figure 8A in Xu et al but the data represents different experimental conditions and samples.

We attempted to contact the authors of this article but despite multiple attempts received no response. The Editor has determined the findings of the study are no longer valid and requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]